| Medalist Diversified REIT (NASDAQ: MDRR) Completes Acquisition of the Brookfield Center |
| |
|
Medalist Diversified REIT (NASDAQ: MDRR), a Virginia-based real estate investment trust that specializes in acquiring, owning and managing value-add commercial real estate in the Southeast region of the U.S., completed the acquisition of the Brookfield Center, a 66,000 sq. ft. flex-industrial property located in Greenville, South Carolina, for a purchase price of $6,700,000.
Why It Matters: The Brookfield Center is 100% occupied and anchored by Gravitopia, the largest developer, operator and franchisor of trampoline parks. The center also includes other national, local and regional tenants. Greenville is 4th among 15 of the fastest-growing large cities in the U.S. and is home to well-known national and international corporations.
Key Quote: “Greenville has been an appealing market to us for some time due to strong and diverse economic drivers. In a recent study, Greenville was named among the top 14 markets that stand out as options for investors seeking growth opportunities in industrial real estate. We believe the Brookfield Center will bring positive growth to our company.” – William Elliott, Vice Chairman & President
The Backstory: MDRR’s strategy is to focus on value-add and opportunistic commercial real estate which is expected to provide an attractive balance of risk and returns. The company utilizes a rigorous, consistent and replicable process for sourcing and conducting due diligence of acquisitions and seeks to maximize operating performance of current properties by utilizing a hands-on approach to property management while monitoring the middle market real estate markets in the southeast for acquisition opportunities and disposal of properties as considered appropriate. Since going public in November 2018, MDRR has declared three quarterly dividends of $0.175 each.
Disclosure
Medalist Diversified REIT (MDRR) is a client of RedChip Companies, Inc. MDRR agreed to pay RedChip Companies, Inc. a monthly cash fee for four (4) months of RedChip investor awareness services.
|
|
| |
|
| cbdMD (NYSE American: YCBD) Becomes Official CBD Partner of 3 Major Podcasts |
| |
|
cbdMD (NYSE American: YCBD), a nationally recognized consumer cannabidiol (CBD) brand, is proud to announce it has become the Official CBD Partner of The Joe Rogan Experience, Armchair Expert with Dax Shepard, and Your Mom's House with Tom Segura and Christina Pazsitzky. The three podcasts are housed under the Public Media Marketing Podcasts Network.
Why It Matters: The Joe Rogan Experience was named the second-most downloaded Apple Podcast of 2018. With millions of downloads per month and over 1.4 billion views on YouTube, the show consistently ranks in the top five for Apple podcast downloads. Armchair Expert with Dax Shepard won the "Breakout Podcast" award at the 2019 iHeartRadio Podcast Awards. Often found ranked in the top 50 for Apple podcasts, the show was the No. 1 most-downloaded new show on Apple Podcasts in 2018. Your Mom's House, hosted by married comedic duo Tom Segura and Christina Pazsitzky, was nominated for the Stitcher Radio Comedy Award. The show has over 81 million views on YouTube and is a top-rated show on Apple Podcasts.
Key Quote: “All three of these shows are giants in their own right. They approach topics in their own way that clearly connects with a massive, receptive audience. By working with these podcasts, our goal is to be able to engage with those audiences and show how CBD is useful for a wholesome wellness regimen.” – Ken Cohn, Chief Marketing Officer
The Backstory: cbdMD is a nationally recognized consumer cannabidiol (CBD) brand whose current products include CBD tinctures, CBD gummies, CBD topicals, CBD bath bombs, and the CBD pet product line PawCBD.
Disclosure
cbdMD (NYSE American: YCBD) is a client of RedChip Companies. YCBD agreed to pay RedChip a monthly cash fee of between $5,000 and $15,000, and 5,000 shares of Rule 144 stock for RedChip investor awareness services. Additionally, the CEO of RedChip Companies owns 13,500 shares of YCBD.
|
|
| |
|
| SPI Energy (NASDAQ: SPI) to Exhibit Its Hemp and CBD Business at CBD Expo Midwest 2019 |
| |
|
SPI Energy (NASDAQ: SPI), a global provider of green energy solutions with strategic investments in green-energy-enabled products and services, today announced that it will exhibit its hemp and CBD business at the CBD Expo Midwest 2019 being held at that the Colorado Convention Center in Denver on October 11 and 12, 2019.
Why It Matters: SPI Energy recently entered the hemp market, and has executed a management services agreement with the Native American Agricultural Company (“NAAC”) to cultivate hemp in the Navajo Nation. The Company also obtained licenses from the Navajo Nation to engage in lab testing, cultivation, processing, wholesale distribution, and retail sales of hemp. The Company has recently signed a lease for a manufacturing facility for its hemp and CBD business in Orange Cove, California. Equipment to produce CBD products is being installed and tested in anticipation of near-term production, which is expected to begin in November 2019.
Key Quote: “We are leveraging this CBD event to enhance the market’s awareness of our hemp and CBD business and to identify potential industry partnerships and customer relationships.” – Xiaofeng Peng, Chairman & CEO
The Backstory: SPI is an established provider of photovoltaic solutions with global operations in key markets in Australia, Europe, Japan and the United States. The Company is leveraging its solar platform and expertise to make strategic investment in green industries with significant growth and earnings potential and/or green-energy-enabled products.
Disclosure
SPI Energy (SPI) is a client of RedChip Companies, Inc. SPI agreed to pay RedChip Companies, Inc. 5,000 shares of Rule 144 stock and a monthly cash fee for 12 months of RedChip investor awareness services and consulting services.
|
|
| |
|
| CTD Holdings (OTCQB: CTDH) Changes Name to Cyclo Therapeutics |
| |
|
Cyclo Therapuetics (OTCQB: CTDH), a clinical stage biotechnology company that develops cyclodextrin-based products for the treatment of disease with unmet medical need, completed its name change from CTD Holdings last week following appropriate regulatory filings with the State of Florida and FINRA.
Why It Matters: The new name better reflects the company’s business as a biotechnology company that develops cyclodextrin-based products for the treatment of disease with unmet medical need, most notably Trappsol® Cyclo™, its proprietary hydroxypropyl beta cyclodextrin drug, for the treatment of Niemann-Pick Disease Type C and Alzheimer’s Disease. The company will continue to trade on the OTCQB Exchange under the symbol CTDH. The new name was overwhelmingly approved by shareholders at their meeting on August 27.
Key Quote: “As we continue to develop our clinical programs in disease areas that can be potentially treated with Trappsol® Cyclo™, the Cyclo Therapeutics, Inc. name better reflects the Company’s main business going forward. We look forward to continued progress and higher recognition of our important biopharmaceutical products.” - Scott Fine, Chairman & CEO
The Backstory: CTD Holdings, Inc. is a clinical-stage biotechnology company that develops cyclodextrin-based products for the treatment of disease. The company’s Trappsol® Cyclo™, an orphan drug designated product in the United States and Europe, is in three ongoing formal clinical trials for Niemann-Pick Disease Type C, a rare and fatal genetic disease, and in an Expanded Access program for late-onset Alzheimer’s Disease.
Disclosure
Cyclo Therapeutics, Inc. (OTCQB: CTDH) is a client of RedChip Companies, Inc. CTDH agreed to pay RedChip Companies, Inc. a monthly cash fee for RedChip investor awareness services and consulting services.
|
|
| |
|
| Immuron (NASDAQ: IMRN) Receives $3.7M in Federal Funding for Traveler’s Diarrhea Preventative Therapy Project |
| |
|
Immuron (NASDAQ: IMRN), which focuses on developing oral immunotherapies for the prevention and treatment of gut-mediated pathogens, announced the Department of Defense approved funding of $3.7 million for the development and testing of a new product designed to protect against traveler’s diarrhea caused by campylobacter and ETEC pathogens.
Why It Matters: Each year, an estimated 1.5 billion episodes of diarrhea are seen in gastroenterology clinics, which leads to deaths of about 2.2 million people. Campylobacter jejuni and ETEC are leading causes of travelers’ diarrhea and represent a major burden for deployed U.S. troops. And despite robust research efforts to develop vaccines against major enteric pathogens, there are currently no licensed vaccines available.
Key Quote: “The ultimate goal of this research effort is to lay the scientific foundation for development of a multi-pathogen product that confers protection against both C. jejuni and ETEC, the predominant causes of infectious diarrhea in deployed warfighters.” – Dr. Frédéric Poly of the NMRC
The Backstory: Immuron already has an ongoing project with the Walter Reed Army Institute of Research focused on shigella. The company sees the collaborative project with the NMRC as enhancing its efforts to raise the profile of its flagship product Travelan and its in-house clinical program to develop IMM-124E as an approved drug to treat traveler's diarrhea.
Disclosure
Immuron Ltd. (NASDAQ: IMRN) is a client of RedChip Companies, Inc. IMRN agreed to pay RedChip Companies, Inc. a monthly cash fee for (3) months of investor awareness services.
|
|
| |
|
| Watch the Piedmont Lithium Webinar to Learn About The Only Conventional Lithium Mine In The US On Tuesday, October 8, 2019 at 11:00 am EST. |
| |
|
Piedmont Lithium (NASDAQ: PLL) President and CEO Keith Phillips will give a presentation and be available during a live Q&A session today, Tuesday, October 8, to discuss recent developments at the company, including new data published in recent months regarding resource estimates and updated scoping study.
Webinar Information:
Oct. 8 at 11 am ET /8 am PT
Location: www.redchip.com/corporate/webinar_register/48
The Background: PLL holds a 100% interest in the Piedmont Lithium Project located within the Carolina Tin-Spodumene Belt (TSB) and along trend to the Hallman Beam and Kings Mountain mines, which historically provided most of the western world’s lithium between the 1950s and the 1980s. The TSB has been described as one of the largest lithium regions in the world and is located approximately 25 miles west of Charlotte, North Carolina.
Disclosure
Piedmont Lithium (NASDAQ: PLL) is a client of RedChip Companies, Inc. PLL agreed to pay RedChip Companies, Inc. a monthly cash fee for six (6) months of RedChip investor awareness services.
|
|
| |
|
| |
| Quote of the Week |
| |
"You may have to work 10 years on a company to make it successful and achieve a healthy return on your investment."
-Phil Sassower, Chairman Phoenix Group |
|
|
|
|
|
|
|
| About RedChip |
| |
| RedChip Companies, an Inc. 5000 company, is an international investor relations, media, and research firm focused on small-cap and mid-cap companies. Since 1992, RedChip has delivered concrete, measurable results for its clients through the most comprehensive service platform in the industry for small-cap and mid-cap companies. These services include a worldwide distribution network for its stock research written by analysts holding the CFA designation; retail and institutional roadshows in major U.S. cities; outbound marketing to stock brokers, RIAs, institutions, and family offices; a digital media investor relations platform that has generated over 2.3 million unique investor views; quarterly global online institutional and retail investor conferences that reach over 10,000 investors annually; "The RedChip Money Report" television show which airs in 100 million homes across the U.S. on The Family Channel; a weekly newsletter delivered to 60,000 investors; TV commercials in local and national markets; corporate and product videos; website design; and traditional investor relation services, which include press release writing, development of investor presentations, quarterly conference call script writing, strategic consulting, capital raising, and more. |
| |
| RedChip Disclosure |
| |
RedChip Companies, Inc. research reports, company profiles and other investor relations materials, publications or presentations, including web content, are based on data obtained from sources we believe to be reliable but are not guaranteed as to accuracy and are not purported to be complete. As such, the information should not be construed as advice designed to meet the particular investment needs of any investor. Any opinions expressed in RedChip reports, company profiles, or other investor relations materials and presentations are subject to change. RedChip Companies and its affiliates may buy and sell shares of securities or options of the issuers mentioned on this website at any time.
RedChip Visibility is a division of RedChip Companies, Inc. and offers research services to paying clients. In the purview of Section 17(b) of the Securities Act of 1933 and in the interest of full disclosure, we call the reader's attention to the fact that the RedChip Companies Inc. is an investor relations firm hired by certain Companies to increase investor awareness to the small-cap equity community.
Stock market investing is inherently risky. RedChip Companies is not responsible for any gains or losses that result from the opinions expressed on this website, in its research reports, company profiles or in other investor relations materials or presentations that it publishes electronically or in print.
We strongly encourage all investors to conduct their own research before making any investment decision. For more information on stock market investing, visit the Securities and Exchange Commission ("SEC") at www.sec.gov and view RedChip’s Disclosures. |
|
| |
|
|
| |
|
|
Copyright © 2019 RedChip Companies, Inc. All Rights Reserved.
You are receiving this message because this email address has signed up to receive News Alerts.
|
|
|
|
